Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ELI Lilly & Co filings on SEC EDGAR ↗
ELI Lilly & EVP, GC & Secretary Anat Hakim Sells $7.01M of Stock
Anat Hakim, EVP, GC & Secretary, sold 5,000 shares of ELI Lilly & Co at $1,402.52 a share, worth $7.01M in total on Nov 2, 2026. Shares held after the trade: 4,137 (-54.7%).
Eli Lilly reported significant growth for the third quarter of 2026, with revenue increasing to $24.40 billion from $17.60 billion in the prior year. Net income for the nine months ended September 30, 2026, rose to $20.94 billion, driven by strong operational performance despite a substantial $7.54 billion charge for acquired in-process research and development.
Eli Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase driven by strong demand for Mounjaro and Zepbound. The company raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 to $92.0 billion, reflecting robust global consumer demand and expanded coverage for obesity care.
Term
Q3 2026
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.”